Wystąpienia zjazdowe opublikowane w czasopismach naukowych



Pobieranie 56.57 Kb.
Data07.05.2016
Rozmiar56.57 Kb.

Wystąpienia zjazdowe opublikowane w czasopismach naukowych

Rodryg Ramlau




  1. M. Bryl, J. Kuczek, R. Ramlau

Rak oskrzelikowo-pęcherzykowy płuca lewego z rozsiewem do OUN – opis przypadku 15-letniej chorej

Onkologia w Praktyce Klinicznej 2008, tom 4, suplement B,str. B43, P23




  1. I. Gołda-Gocka, B. Jezierska, R. Ramlau

Nietypowa lokalizacja przerzutów nowotworowych u 47-letniej chorej z niedrobnokomórkowym rakiem płuca – opis przypadku

Onkologia w Praktyce Klinicznej 2008, tom 4, suplement B,str. B43, P21




  1. Ł. Spychalski, M. Bryl, R. Ramlau, J. Mądrzak

Ocena czynników rakotwórczych w złośliwym międzybłoniaku opłucnej na podstawie analizy 22 przypadków

Onkologia w Praktyce Klinicznej 2008, tom 4, suplement B,str. B43, P19




  1. CC. Zieliński, S.Yang, A. Santoro, R. Ramlau, AM. Liepa, P. Peterson, T. Brodowicz, J. Madhavan, FA. Franke, , B. Cucevic

Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study.

Journal of Clinical Oncology, ASCO 2008, vol. 26, No 15S, Part I, str. 439 (8063)




  1. P. Delmar, EH. Tan, AG. Płużanska, R. Ramlau, M. Reck, P. McLoughlin

MERIT: Analysis of differential gene expression in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib.

Journal of Clinical Oncology, ASCO 2008, vol. 26, No 15S, Part I, str. 435 (8046)




  1. R. Ramlau, V. Westeel, Z. Papai, A. Riviere, A. Madroszyk, P. Koralewski, G. Lacoste, B. Acres, JM. Limacher, E. Quoix

Randomized phase Iib trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patieents with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology, ASCO 2008, vol. 26, No 15S, Part I, str. 429 (8023)




  1. R. Pirker, A. Szczęsna, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, U. Gatzemeier, E. Bajeta, M. Emig, JR Pereira,

A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology, ASCO 2008, vol. 26, No 15S, Part I, str. 6 (3)




  1. R. Pirker, R. Ramlau, W. Schuette, P. Zatloukal, I. Ferreira, T. Lillie, J. Vansteenkiste

A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

Journal of Thoracic Oncology, Supplement, Vol. 2, nr 8, Aug 2007, str.433




  1. T. Eng Huat, R. Ramlau, A. Płużanska, HP. Kuo, B. Klughammer, M. Kockx, M. Carreras, V. Lutz, L. Essioux, J. Baselga

MERIT: a prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology, Supplement, Vol. 2, nr 8, Aug 2007, str.394




  1. M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, C. Manegold

BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology, Supplement, Vol. 2, nr 8, Aug 2007, str.360




  1. R. Ramlau, J. Bennouna, T. Eng Huat, B. Biesma, A. Santoro, C. Boni, H. Klein, K. Leśniewski, R. Mesia, U. Gatzemeier

Phase III study of vinflunine versus docetxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen

Journal of Thoracic Oncology, Supplement, Vol. 2, nr 8, Aug 2007, str.317




  1. C. Manegold, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, M. Reck

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advancedor recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

Journal of Clinical Oncology, vol 25, No 18S Part I of II, June 20, 2007, 388s, 7514

Asco Annual Meeting Proceesings


  1. M. Krzakowski, J. Douillard, R. Ramlau, J. Janssen, A. Szczęsna, P. Zatloukal, J. von Pawel, O. Hansen, X. Sun

Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum- containing regimen.

Journal of Clinical Oncology, vol 25, No 18S Part I of II, June 20, 2007, 387s, 7511

Asco Annual Meeting Proceesings


  1. R. Ramlau, A. Woźniak, J. Żurawski, E. Kaczmarek, A. Górna

Ocena nasilenia angiogenezy i ekspresja E-kadheryny w raku płaskonabłonkowym płuc u chorych po indukcyjnej chemioterapii

Nowotwory, Journal of Oncology, 2006, vol. 56, supl.4, str. 163, 488




  1. W. Dyszkiewicz, C. Piwkowski, M. Kasprzyk, J. Adamczak, K. Pawlak, B. Fik, R. Ramlau

Wpływ chemioterapii neoadiuwantowej na występowanie powikłań pooperacyjnych u chorych po radykalnej resekcji z powodu raka płuca

Nowotwory, Journal of Oncology, 2006, vol. 56, supl.4, str. 140, 414





  1. M. Matecka-Nowak, M. Bryl, M. Fundowicz, A. Kołodziej, R. Ramlau

Przypadki całkowitej remisji w postaci ograniczonej raka drobnokomórkowego płuca – doświadczenia Wielkopolskiego Centrum Onkologii i Wielkopolskiego Centrum Chorób Płuc i Gruźlicy

Nowotwory, Journal of Oncology, 2006, vol. 56, supl.4, str.119,349




  1. J.Jassem, R. Ramlau, A. Santoro, W. Schuette, A. Chemaissani, S. Hong, J. Blatter, S Adachi, A. Hanauske, Ch. Manegold

A randomized Phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM).

Annals of Oncology, Esmo, Sep 2006, Vol. 17, Supl. 9, 715O




  1. F Salazar, M Cobo, R Ramlau, B Massuti, F Cardenal, M Provencio, N Vinolas, GL Vivanco, MA Munoz, R Rosell

Mitotic checkpoint gene CHFR methylation in pretreatment serum DNA of docetaxel (DOC)/Ciplatin (CIS)-treated Stage IV non-small-cell lung cancer (NSCLC) patients (P)

Annals of Oncology, Esmo, Sep 2006, Vol. 17, Supl. 9, 740P




  1. J Rolski, R Ramlau, M Dediu, PA Witman, RR Bandekar, M Russo

Phase II trial of the neurokinin-1 antagonist casopitant meylate for the prevention of chemotherapy-induced neusea/vomiting (CINV) in cancer patients (PTS) receiving highly emetogenic chemotherapy (HEC) : subgroup analysis by cisplatin dose

Annals of Oncology, Esmo, Sep 2006, Vol. 17, Supl. 9, 1052P




  1. P. Peterson, R. Ramlau

Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintanance therapy.

ASCO 2006, 7140




  1. J. Rolski, R. Ramlau, M. Dediu, M.W. Russo, G.A. Ross, R. Bandekar, S.M. Grunberg

Randomized phase II trial of neurokinin-1 receptor antagonised casopitant mesylate with

ondansetron (ond) /dexamethasone (dex) for chemotherapy- induced nausea/vomitting

(CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).

ASCO 2006, 8513




  1. Negro-Vilar, U. Gatzemeier, R. Ramlau, S.L. Sun, Herman, J.K. Zhang, Z.

Dziewanowska

Biomarker correlates of survival in NSCLC : Role of RXRB and PPRy in mediating bexarotene impact on patient survival.

ASCO 2006, 7227


  1. J.R. Eckardt, R. Ramlau, R. Gervais, F. Shepherd, M. O’Brien, B. Dharan, P. Wissel, G.

Ross

Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and

small cell lung cancer (SCLC).

ASCO 2006, 7092




  1. Thomas Brodowicz, Maciej Krzakowski, Matjaz Zwitter, Valentina Tzekova, Rodryg

Ramlau, Nicolae Ghilezan, Tudor Ciuleanu, Branka Cucevic, Kalman Gyurkovits, Ernst Ulsperger, Jacek Jassem, Mislav Grgic, Pinar Saip, Maria Szilasi, Christoph Wiltschke, Maria Wagnerova, Natalya Oskina, Victoria Soldatenkova, Christoph Zieliński, Miklos Wenczl and for the Central European Cooperative Oncology Group (CECOG).

Cisplatin and gemtacibine first-line chemotherapy followed by maintenance gemtacibine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Lung Cancer, 29 March 2006


  1. E. Sierko, P. Tokajuk, R. Ramlau et al.

Immunohistochemical Localization of Protein Z (ZP) and Protein Z-Dependent Protease

Inhibitor (ZPI) in Situ in Human Malignant Tumors.

Journal of Thrombosis and Haemostasis, Vol. 3, Supplement 1, P0718


  1. E. Sierko, R. Ramlau et al.

Expression of Protein Z-Dependent Protease Inhibitor (ZPI) In Situ in Different Malignant

Tumors.


Blood, Journal of The American Society of Hematology, Vol. 104, 16 November 2004,

76b, Abstract# 3959




  1. E. Sierko, P. Tokajuk, R. Ramlau et al.

Localization of Protein Z (PZ) In Situ in Human Neoplastic Tissues.

Blood, Journal of The American Society of Hematology, Vol. 104, 16 November 2004,

76b, Abstract# 3958


  1. Szczesna, M. Taron, G. Robinet, R. Ramlau et al.

EGFR mutation analysis in a randomized phase II study of cetuximab (Erbitux™) in

combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment

of advanced non-small-cell lung cancer (NSCLC) patients (pts)

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S377 (P-976)




  1. Mennecier, R. Ramlau et al.

A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in

association with cisplatin and vinorelbine in patients with non small cell lung cancer

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S373 (P-963)


  1. H. Wakelee, G. Middleton, D. Dunlop, C. Kelly, R. Ramlau et al.

Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study

in patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S274 (P-592)


  1. P. Souquet, R. Ramlau et al.

Vinflunine (VFL) and cisplatin (CDDP) combination in first line treatment of advanced

non-small lung cancer (NSCLC). Final results of a phase II study

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S269 (P-574)


  1. R. Ramlau et al.

Evaluation of bexarotene (Targretin®) in combination with cisplatin and vinorelbine in

chemiotherapy-naive patients with advanced stage IIIb/IV non-small cell lung cancer

(NSCLC)

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S266 (P-562)




  1. Belani, J. von Pawel, A. Pluzanska, V. Gorbounova, E. Kaukel, K. Mattson, R. Ramlau

et al.

Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus

vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer

(NSCLC) : Analyses by gender

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S235 (P-452)


  1. R. Rosell, M. De Lena, F. Carpagnano, R. Ramlau et al.

ANITA : Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in

completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts)

Lung Cancer, Vol. 49, Supplement 2, July 2005, No S3 (Pr3)


  1. T. Velu, R. Ramlau, E. Quoix et al.

A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC 1-IL2) in

association with chemotherapy in patients with non-small cell lung cancer.

Supplement to Journal of Clinical Oncology, Vol. 23, No. 16S, Part I of II, June 1, 2005,

653s, 7132




  1. J. Jassem, P. Zatloukal, R. Ramlau et al.

A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus

cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-

small cell lung cancer (NSCLC).

Supplement to Journal of Clinical Oncology, Vol. 23, No. 16S, Part I of II, June 1, 2005,

627s, LBA7024


  1. R. Ramlau, R. Gervais, M. Krzakowski et al.

Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer.

Results from an open-label, phase III study (387) comparing oral topotecan to

intravenous docetaxel.

Supplement to Journal of Clinical Oncology, Vol. 23, No. 16S, Part I of II, June 1, 2005,

625s, 7017


  1. M. Gottfried, R. Ramlau,

The Vinorelbine (NAVELBINE/NVB)-based triplet with Ifosfamide (IFO) and Cisplatin (NIP) allows resection in marginally unresectable Non-Small Cell Lung Cancer (NSCLC) patients (pts) without delay in surgery.

Annals of Oncology, Vol.15, October-November 2004, s.173.




  1. M. Bryl, R. Ramlau,

Treatment of advanced invasive thymomas in experience of Oncology Department of Regional Lung Diseases Centre in Poznań .

Lung Cancer , Vol.45. No.3, September 2004, S 81.





  1. R. Ramlau, J. Kuczek, M. Bryl

Perspectives of adjuvant therapy in clinical trial in patients who have had radical resection for non-small-cell lung cancer .

Lung Cancer , Vol.45. No.3, September 2004, S 58.




  1. R. Ramlau, M.Bryl, E. Nowak, I.Gołda-Gocka.

Analysis of survival in non-small-cell lung cancer patients (stages IIIB anmd IV) treated with platinum-based chemotherapy and randomly allocated to receive or not epoetin alfa in case of anaemia during treatment, based on a group of patients enrolled to protocol EPO-INT 49 in Regional Lung Diseases Centre in Poznań.

Lung Cancer , Vol.45. No.3, September 2004, S 58.




  1. R. Ramlau, B.Jezierska

Multicenter randomized phase III trial comparing the use of Targretin capsules in combination with cisplatin and vinorelbin versus chemiotherapy alone in untreated patients with advanced non-small-cell lung cancer staged IIIB and IV.

Lung Cancer , Vol.45. No.3, September 2004, S 56.




  1. Sierko, R. Ramlau i wsp.

Localization of protein Z-dependent protease inhibitor (ZPI) in non-small-cell lung cancer tissue (NSCLC).

Lung Cancer , Vol.45. No.3, September 2004, S 41.




  1. Sierko, P. Tokajuk, R. Ramlau i wsp.

Immunohistochemical localization of protein Z (PZ) in situ in non-small-cell lung cancer (NSCLC).

Lung Cancer , Vol.45. No.3, September 2004, S 40.




  1. Sierko, R. Ramlau i wsp.

Expression of TF (tissue factor) and tissue factor pathway inhibitors (TFPI, TFPI-2) in situ in non-small-cell lung cancer (NSCLC).

Lung Cancer , Vol.45. No.3, September 2004, S 40.




  1. M. Gottfried, R.Ramlau i wsp.

Vinorelbine (NVB)-based triplet with ifosfamide (IFO) and cisplatin (NIP) as induction chemotherapy (CT ) to increase resection rate in marginally unresectable non-small cell lung cancer (NSCLC) patients (pts).

Proceedings of ASCO, Vol.23.No.40, June 2004, S 654.




  1. R.Ramlau i wsp.

Results of a phase I/II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC).

Proceedings of ASCO, Vol.23.No.40, June 2004, S 640.




  1. M.Krzakowski, M. Wenczl, T. Brodowicz, V.Tzekova, R.Ramlau i wsp.

Gemcitabine and cisplatin (GC) +/- subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC); Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG).

Proceedings of ASCO, Vol.23.No.40, June 2004, S 630.




  1. R. Rosell, C. Daniel, R.Ramlau i wsp.

Randomized phase II study of cetuximab in combination with cisplatin (C ) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC).

Proceedings of ASCO, Vol.23.No.40, June 2004, S 618.




  1. M. De Lena, R.Ramlau i wsp.

Phase II of oral vinorelbine ( NVB oral ) in combination with Cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non-small-cell lung cancer (NSCLC).

Proceedings of ASCO, Vol.23.No.40, June 2004, S 697.




  1. C.Manegold J.Debus E.Buchholz,G.V.Scagliotti,U.Ricardi,F.Cardenal,K.Mattson

R.Ramlau i wsp.

A phase II randomized study comparing docetaxel / cisplatin induction therapy followed by thoracic radiotherapy with or without weekly docetaxel in unresectable stage IIIA-IIIB non-small cell lung cancer.

European Journal of Cancer, Vol.1,No.5,September 2003, S248, 827.


  1. R.Ramlau i wsp.

A full Navelbine Oral ( NVB oral ) treatment in combination with Cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non-small-cell lung cancer (NSCLC).

European Journal of Cancer, Vol.1.No.5, September 2003, S247,823.




  1. M.Krzakowski, R.Ramlau i wsp.

Phase I / II and pharmacokinetic study of Vinflunine ( VFL ) in combination with cisplatin (CDDP ) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients : Preliminary results.

European Journal of Cancer, Vol.1 No.5, September 2003, S241, 803.




  1. R.Rosell, R. Ramlau i wsp.

Randomized phase II clinical trial of cetuximab in combination with cisplatin ( C ) and vinorelbine ( V ) or CV alone in patients with advanced Epidermal Growth Factor Receptor (EGFR)- expressing non-small –cell lung cancer (NSCLC).

European Journal of Cancer, Vol.1 No.5, September 2003, S21, 55.




  1. Manegold C, Ramlau R, Scagliotti GV, Buchholz E, Szczęsna A, Cardenal F, Mattson KV, Van Zandwijk N, Morel A, Price A,

A phase II randomized study of thoracic radiotherapy with or without weekly docetaxel following docetaxel-cisplatin induction chemotherapy in unresectable stage IIIA-IIIB non-small cell lung cancer

Lung Cancer, 2003, vol. 41, supplement 2, S243, P-601



  1. Krzakowski M, Wenczl m, Brodowicz T, Tzekova V, Ramlau R, Ghilezan N, Cucevic B, Gyurkovits K, Ernst U, Zielinski C, Zwitter M

Gemcitabine and Cisplatin (GC) =/- Subsequent Maintenance Therapy with Single-Agent Gemcitabine in Advenced Non-small Cell Lung Cancer (NSCLC): Preliminary Resulats of a Randomized Trial of the Central European Cooperative Oncology Group (CECOG)

Lung Cancer, 2003, vol. 41, supplement 2, S29, O-88




  1. M.De Lena, R. Ramlau i wsp.

Phase II study of vinorelbine oral (NVB oral) in combination with cisplatin (P) followed by consolidation therapy with vinorelbine oral single agent in advanced non small-cell lung cancer (NSCLC).

Proceedings of ASCO, vol.22 , 2003 , 2633, 655.




  1. U.Gatzemeier, R. Rosell, R. Ramlau i wsp.

Cetuximab (C225) in combination with cisplatin / vinorelbin alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC).

Proceedings of ASCO, vol.22 , 2003, 2582 , 642.




  1. J. Jassem, P. Kosmidis, R. Ramlau i wsp.

Oral vinorelbine ( NVB oral ) in combination with cisplatin ( P ) in advanced non- small cell lung cancer ( NSCLC ): Final results of a phase II study.

Annals of Oncology , vol.13 , 2002 , supplement 5, 144 ( 527P ).




  1. R. Ramlau , G.V.Scagliotti , Ch. Manegold i wsp.

Radiotherapy and concurrent weekly docetaxel following cisplatin-docetaxel induction chemotherapy in unresectable Stage III B non-small –cell lung cancer : A randomised phase II trial.

Annals of Oncology , vol. 13, 2002 , supplement 5, 134 ( 491 PD ).




  1. G.V.Scagliotti, C. Manegold, E. Buchholz, D.Zierhut, A.Szczęsna, R.Ramlau i wsp.

Randomized phase II study evaluating the feasibility of thoracic radiotherapy with or without weekly docetaxel ( Taxotere ) following induction chemotherapy with cisplatin ( DDP ) and docetaxel in unresectable stage III A/B non small cell lung cancer.

Proceeding of ASCO, vol. 21, 2002, 1279, 320a.




  1. J.Jassem , P. Kosmidis, R. Ramlau i wsp.

Navelbine ( NVB ) oral in combination with cisplatin ( P ) .An active regimen in advanced non-small cell lung cancer ( NSCLC ).

Proceeding of ASCO , vol. 21, 2002 , 1242, 311a.




  1. R.J.Gralla, J.Rodrigues, J.Von Pawel, A, Płużańska, E.Kaukel, K.Mattson, F.V.Fossella, A.Szczęsna, R.Ramlau i wsp.

Prospective analysis of quality of life ( QOL ) in a randomised multinational phase III study comparing docetaxel ( D ) plus either cisplatin ( C ) or carboplatin ( Cb ) with vinorelbine plus cisplatin ( VC ) in patients with advanced non-small cell lung cancer (NSCLC ).

Proceedings of ASCO, vol.21, 2002, 1196,300a.





  1. M.Skrzypski , R.Ramlau , i wsp.

Mutations of p16 and p53 genes in non-small cell lung cancer.

Współczesna Onkologia , 2001 , suplement, 5 , 68 , ( 87 ).




  1. R. Ramlau , A.Płużańska , A.Szczęsna i wsp.

A multicenter randomized phase III study of docetaxel +cisplatin and docetaxel+carboplatin vs. vinorelbin +cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer.

Współczesna Onkologia , 2001 , suplement , 5 , 42 , (37 ).




  1. R. Ramlau , W. Dyszkiewicz i wsp.

Chemioterapia adjuwantowa po radykalnym leczeniu chirurgicznym niedrobnokomórkowego raka płuca- prospektywne międzynarodowe badanie randomizowane ANITA.

Współczesna Onkologia , 2001 , suplement, 5 , 38 , ( 30 ).




  1. E. Jassem , R. Ramlau i wsp.

Molekularne zaburzenia w niedrobnokomórkowym raku płuca.

Pneumonologia i Alergologia Polska, 2001 , Vol.69 , 7 – 8 , 448.




  1. B.Weryńska, R. Ramlau , R.Jankowska, M.Podolak-Dawidziak i wsp.

Stężenie trombopoetyny ( TPO ) w surowicy u chorych z nadplytkowością w przebiegu raka płuca i z nadpłytkowością samoistną.

Pneumonologia i Alergologia Polska , 2001, Vol.69, 7-8 ,464 – 465 .




  1. P.Zatloukal , J.Jassem , A. Depierre , R.Ramlau i wsp.

Oral navelbine versus intravenous navelbine in advanced NSCLC.

Lung Cancer , supplement 1 to Vol.32, May 2001 , S 50.




  1. R.Ramlau , W.Dyszkiewicz i wsp.

Prospektywne randomizowane badanie chemioterapii adjuwantowej po radykalnym leczeniu chirurgicznym w niedrobnokomórkowym raku płuca – w ramach badania międzynarodowego ANITA.

Onkologia Polska , 2000 , suplement 1, Vol.3 , 79.




  1. R.Ramlau , E.Nowak

Leczenie bifosfonianami przerzutów do kości w przebiegu raka płuca.

Onkologia Polska , 2000, suplement 1, Vol.3, 74 .




  1. M.Sieciechowicz , R. Ramlau

Ocena jakości życia u chorych na raka niedrobnokomórkowego płuca w stopniu IIIB i IV leczonych Gemcytabiną i Cisplatyną.

Onkologia Polska , 2000 , suplement 1, Vol.3, 73-74.




  1. J. Jassem , M.Krzakowski , K.Roszkowski. R. Ramlau i wsp.

A phase II study of Gemcitabine plus Cisplatin in patients with advanced non-small cell lung cancer:Clinical outcomes and quality of life.

Onkologia Polska , 2000 , suplement 1, Vol.3, S3 , 67.





  1. A.Skowron , J.Brandys, T.Szczęsny , R. Ramlau i wsp.

Analiza farmakoekonomiczna chemioterapii w niedrobnokomórkowym raku płuca.

Onkologia Polska , 2000 , suplement 1 , Vol.3 , 65 – 66 .




  1. J.Jassem , A.Depierre, R. Ramlau i wsp.

Wieloośrodkowe randomizowane badanie II fazy porównujące doustną Navelbinę z dożylną Navelbiną u chorych na zaawansowanego niedrobnokomórkowego raka płuca.

Onkologia Polska , 2000 , suplement 1 , Vol.3 , 65 .




  1. R. Ramlau ,J. Jakóbkiewicz , R.Dziadziuszko , E, Jassem i wsp.

Mutacje genu p16 u chorych na niedrobnokomórkowego raka płuca .

Onkologia Polska , 2000 , suplement 1 , Vol. 3 , 63.




  1. R. Ramlau , M.Podolak – Dawidziak , i wsp.

Stężenie rozpuszczalnego receptora dla a transferyny ( sTfR ) w surowicy chorych na raka płuca.

Onkologia Polska , 2000 , suplement 1 , Vol 3, 43 – 44 .




  1. J. Kinas-Budzisz , R. Ramlau

Obecność zachowań asertywnych w życiu człowieka a ryzyko choroby nowotworowej.

Onkologia Polska , 2000 , suplement 1 , Vol. 3 , 39-40




  1. R. Ramlau , i wsp.

Immunotherapy with the use of interleukin-2, interferon-a2 and 5fluorouracil in the treatment of metastatic kidney carcinoma.

Immunology Letters ,2000 , Vol.73 , No.2,3 , 279 , Abstr 837




  1. F.Shepherd, J.Dancey, R.Ramlau i wsp.

A prospective randomised trial of Taxotere versus best supportive care(BSC) in patients with non-small cell lung cancer previously treated with platinum –based chemotherapy: Survival update.

Lung Cancer , 2000 , Vol.29 , Suppl. 1 , 60 , (Abstr 193 )




  1. A.Depierre, J.Jassem , R. Ramlau i wsp.

Feasibility and safety of Navelbine oral with an intrapatient dose escalation versus Navelbine intravenous in advanced, metastatic non –small cell lung cancer.

Lung Cancer , 2000 ,Vol. 29 ( Suppl 1 ):35 ( Abstr 112 ).




  1. F.Shepherd , R. Ramlau i wsp.

Randomized study of Taxotere versus Best supportive Care iin non-small cell lung cancer patients previously treated with platinum based chemotherapy.

Proceedings of ASCO, Vol. 18 , 1999 , 463a , No.1784




  1. J.Dancey , F. Shepherd, R. Ramlau i wsp.

Quality of life (QOL) Asssessment in randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer patients previously treated with platinum –based chemotherapy.

Proceedings of ASCO, Vol.18 , 1999, 491a, No.1896





  1. Shepherd, R. Gralla, R. Ramlau i wsp.

Randomised study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy.

The European Journal of Cancer , Vol.35 , supplement 4 , September 1999 , S 247




  1. J.Jassem, M.Krzakowski, K,Roszkowski, M.Somiński ,R.Ramlau i wsp.

Phase II study of Gemcitabine and Cisplatin in advanced NSCLC.Focus on quality of life ( QoL ).

Lung Cancer , vol. 25 , supplement No.1 ( 1999 ), S 24.




  1. R. Ramlau, M.Sieciechowicz

Gemcytabina i Cisplatyna w leczeniu raka niedrobnokomórkowego płuc w stopniu zaawansowania IIIB,IV

Pneumonologia i Alergologia Polska, suplement 2 , 1998 , t.66, 184




  1. M .Zabel, A.Kaczmarek,Z.Kycler,R.Lukianow,J.Markowska, P.Murawa, A.Pater, C.Ramlau, R.Ramlau,J.Surdyk

Badanie wrazliwosci nowotworów na cytostatyki w warunkach in vitro.

Nowotwory, suplement, 1990 , 246 – 247.




  1. F.de Waard, R.Ramlau

A pilot study of weight reduction in obese postmenopausal women with breast cancer

Nowotwory, suplement, 1990 , 226.




  1. P.Tomczak,B.Herman, C.Ramlau, R.Ramlau

Ciekawy przypadek nowotworu u dwóch młodych mężczyzn z umiejscowieniem w obrębie sutka.

Nowotwory,suplement,1990,221 – 222




  1. C.Ramlau, P.Tomczak, R.Ramlau, J.Zaluski

Guzy kości w materiale Oddziału Chemioterapii Kliniki Onkologii AM w Poznaniu

Nowotwory,suplement,1990,186-187.




  1. C.Ramlau,M.Litwiniuk, P.Tomczak,R.Ramlau

Liposarcoma w materiale Oddziału Chemioterapii Kliniki Onkologii AM w Poznaniu.

Nowotwory, suplement,1990,185-186.




  1. J.Luczak, M.Okupny, R.Ramlau,W.Kubiak

Ocena morfiny stosowanej podskórnie w zwalczaniu bólu u chorych z zaawansowaną chorobą nowotworową.

Nowotwory,suplement,1990,127-128




  1. J.Luczak,M.Okupny,W.Kubiak,R.Ramlau

Przydatność doustnej morfiny w zwalczaniu bólu, kaszlu i duszności u chorych z zaawansowaną chorobą nowotworową w warunkach opieki domowej.

Nowotwory, suplement,1990,129-127








©absta.pl 2016
wyślij wiadomość

    Strona główna